

Type of paper: Research article

1 **Proteomic and lipidomic analysis of primary mouse hepatocytes exposed to metal and**
2 **metal oxide nanoparticles**

3

4 Sara Tedesco^{1*}, Narges Bayat^{2*}, Gabriela Danielsson², Xabier Buque³, Patricia Aspichueta³, Olatz
5 Fresnedo³ and Susana Cristobal^{1,3,4,5}

6

7 ¹ Department of Clinical and Experimental Medicine, Health Science Faculty, Linköping University,
8 Linköping, Sweden. ² Department of Biochemistry and Biophysics, Arrhenius laboratories, Stockholm
9 University, Stockholm, Sweden. ³ Department of Physiology, Faculty of Medicine and Dentistry,
10 University of the Basque Country UPV/EHU, Leioa, Spain. ⁴ IKERBASQUE, Basque Foundation for
11 Science, Bilbao, Spain.

12 *Both authors have equally contributed

13

14 ⁵**Corresponding author:**

15 Prof. Susana Cristobal, Department of Clinical and Experimental Medicine, Cell Biology, level 13, Faculty
16 of Health Science Linköping University SE-581 85 Linköping, Sweden. Email: Susana.Cristobal@liu.se
17 Tel: +46-10-1030881

18

19

20 **Abstract**

21 The global analysis of the cellular lipid and protein content upon exposure to metal and metal oxide
22 nanoparticles (NPs) can provide an overview of the possible impact of exposure. Proteomic analysis has
23 been applied to understand the nanoimpact however the relevance of the alteration on the lipidic profile

24 has been underestimated. In our study, primary mouse hepatocytes were treated with ultra-small (US)
25 TiO₂-USNPs as well as ZnO-NPs, CuO-NPs and Ag-NPs. The protein extracts were analysed by 2D-DIGE
26 and quantified by imaging software and the selected differentially expressed proteins were identified by
27 nLC-ESI-MS/MS. In parallel, lipidomic analysis of the samples was performed using thin layer
28 chromatography (TLC) and analyzed by imaging software. Our findings show an overall ranking of the
29 nanoimpact at the cellular and molecular level: TiO₂-USNPs<ZnO-NPs<Ag-NPs<CuO-NPs. CuO-NPs and
30 Ag-NPs were cytotoxic while ZnO-NPs and CuO-NPs had oxidative capacity. TiO₂-USNPs did not have
31 oxidative capacity and were not cytotoxic. The most common cellular impact of the exposure was the
32 down-regulation of proteins. The proteins identified were involved in urea cycle, lipid metabolism,
33 electron transport chain, metabolism signaling, cellular structure and we could also identify nuclear
34 proteins. CuO-NPs exposure decreased phosphatidylethanolamine and phosphatidylinositol and caused
35 down-regulation of electron transferring protein subunit beta. Ag-NPs exposure caused increased of total
36 lipids and triacylglycerol and decrease of sphingomyelin. TiO₂-USNPs also caused decrease of
37 sphingomyelin as well as up-regulation of ATP synthase and electron transferring protein alfa. ZnO-NPs
38 affected the proteome in a concentration-independent manner with down-regulation of RNA helicase.
39 ZnO-NPs exposure did not affect the cellular lipids. To our knowledge this work represents the first
40 integrated proteomic and lipidomic approach to study the effect of NPs exposure to primary mouse
41 hepatocytes *in vitro*.

42

43

44 **Keywords:** nanoparticles, hepatocytes, proteomics, lipidomics, mass spectrometry, toxicity

45

46 **Abbreviations**

47 2D-DIGE: two-dimensional difference gel electrophoresis; NPs: nanoparticles; USNPs: ultra-small
48 nanoparticles; ROS: reactive oxygen species; DLS: dynamic light scattering

49

50

51 **1. Introduction**

52 The rapid development of nanotechnology and its applications has led to a growing and widespread use of
53 products containing NPs in a myriad of areas as diverse as electronics, cosmetics, food additives, and
54 medicine [1]. Metal and metal oxide nanoparticles (NPs) such as Silver (Ag) titanium (IV) dioxide
55 (TiO₂), zinc oxide (ZnO), and copper oxide (CuO) are some of the most common industrial NPs additives

56 for various applications [2, 3]. We have previously shown the cytotoxicity as well as the cellular ultra-
57 structural effects of these NPs on *Saccharomyces cerevisiae* [4]. In this study we focus on the effects of the
58 mentioned NPs on hepatocytes considering that for those NPs that succeed in entering the bloodstream,
59 either after inhalation, via the gastrointestinal tract or dermal absorption, the liver is one of the most
60 important targets. Previous studies have demonstrated high accumulation and retention of NPs in liver after
61 injection and digestion respectively [5-7]. TiO₂-NPs are one of the most studied NPs due to their extensive
62 application in paints, cosmetics, and sunscreens [8, 9]. The interest on ultra-small NPs (USNPs), size range
63 between 1-3 nm, has increased enormously for its applicability to optics and theranostics [10, 11]. The
64 uniqueness of USNPs arises from possessing an extremely large surface area to volume ratio. This
65 property enables them to be regarded as large molecules and accentuating the properties derived from
66 interfacial interactions of the surface atoms with the solvent [12, 13]. A previous study has shown that gold
67 USNPs were able to penetrate deeply into tumor spheroids, showed high levels of accumulation in tumor
68 tissue in mice, and were distributed throughout the cytoplasm and nucleus of cancer cells in vitro and in
69 vivo, whereas at 15 nm, they were found only in the cytoplasm, where they formed aggregates [14].
70 However, information about the toxicity and effects of TiO₂-USNPs on the cellular response is scarce.

71 Another NPs of great interest are ZnO- NPs, which due to their remarkable ultra-violet (UV) absorption
72 and optical properties, are included in personal care products such as toothpaste, cosmetics, and textiles
73 [15]. However exposure to ZnO-NPs through inhalation has been shown to cause toxicity through a battery
74 of mechanism including cell stress and inflammation [16]. It has been observed that ZnO-NPs elucidate
75 their toxicity by release of ions which alter Zn homeostasis [17, 18]. This is particularly important in
76 hepatocytes as Zn is an essential trace element required for normal cell growth and function, and Zn
77 deficiency/altered metabolism is observed in many types of liver diseases [19, 20]. CuO-NPs are
78 extensively applied due to their potential applications as gas sensors, catalysts, and superconductors [21].
79 Cu ions are essential and function as cofactor of many enzymatic reactions and would be cycling between
80 the two redox states. This process can be the source of reactive oxygen species (ROS) [22]. Indeed as
81 hepatocytes are responsible for the Cu ions balance of the body, they are a major target of exposure and
82 line of defense in the case of exposure to CuO-NP. Previous studies have shown that toxicity of CuO-NPs
83 as well as their interference with the Cu ion homeostasis in hepatocytes [23, 24]. Exposure to CuO-NPs
84 has been shown to affect the fatty acid composition *Tetrahymena thermophila* [25]. Toxicity associated
85 with CuO-NPs has been connected with release of Cu ions as well as with oxidative stress. Ag-NPs have
86 been widely used in personal products, food service, medical instruments, and textiles because of their
87 antibacterial effects [26, 27]. Internalized Ag-NPs can release ions which may lead to cellular metabolism

88 and mitochondrial dysfunction, inducing directly and indirectly ROS generation [2, 28]. Previous studies
89 have also shown the toxicity of Ag-NPs in hepatocytes by affecting homeostasis and reducing albumin
90 release [5] or by stimulating glycogenolysis [29]. Numerous studies have demonstrated that the NPs
91 interaction with serum proteins and cell membranes receptors is determined by the NPs design, affecting
92 cellular uptake, gene and protein expression, and toxicity [30]. It has been reported the interaction of NPs
93 with proteins, lipoproteins and plasma membrane might compromise its fluidity and integrity and/or
94 facilitate the entry of the NPs [31]. However most of the studies showing NPs uptake have been mainly
95 conducted on immortalized cell lines, whereas little is known those effects on primary cells [30]. Primary
96 hepatocytes cultures represent a powerful *in vitro* system, as these cells are directly isolated from the
97 animal keeping the parental specific properties of the liver (*in vivo*) from which they are derived unaltered.
98 The aim of this study is to provide a functional understanding of the impact of the studied NPs in primary
99 hepatocytes. The strategy is to apply a combined OMICs approach, lipidomics and proteomics that could
100 integrated the functional role of lipids in the cellular response. Therefore, the differentially expressed
101 proteins identified in combination with the changes in the lipid composition of the membranes may
102 contribute to understanding the possible effects and exposure risks of the selected NPs. The field of
103 nanotoxicology is aiming to fill gaps on the NP impact and system biology strategies could lead to evaluate
104 possible outcome adverse pathways for human, animals and the environment.

105

106 **2. Material and Methods**

107 *NPs characterization*

108 The following NPs were used in this study: titanium (IV) oxide, 14027, dry nanopowder, rutile, average
109 particle size: 1-3 nm (Plasmachem GmbH, Münster, Germany), ZnO nano powder, 544906, average size
110 <100 nm, Copper (II) oxide nano powder, 544868, average size <50 nm, Ag-NPs aqueous colloidal
111 solution, 0.1 mg/mL, and average particle size: 10 nm were purchased by Sigma (St. Louis, MO, USA).
112 All NPs stock suspensions were prepared by suspending NPs in hepatocytes culture medium. The
113 suspensions were prepared freshly, sonicated in a water bath sonicator for 30 min and vortexed vigorously
114 before each assessment. The average hydrodynamic size by DLS measurement and the zeta potential were
115 determined using a Malvern Zetasizer Nano series V5.03 (PSS0012-16 Malvern Instruments,
116 Worcestershire. UK) and the analysis program DTS (dispersion technology software, Malvern
117 Instruments). Two concentrations of NPs were used in order to assess their size and zeta potential: 5 and
118 500 mg/L that correspond to the exposure and the stock suspension concentration, respectively. The
119 measurements were conducted in clear disposable capillary cells (DTS1060).

120 *Cell-free dichlorofluorescein (DCFH) assay*

121 The study of the oxidative potential of NPs was measured by a cell free method described by Foucaud *et*
122 *al.* [32] and modified for this study. Briefly, 2',7' dichlorofluorescein diacetate (DCFH-DA, Molecular
123 Probes D-399) at 2.2 mM was hydrolyzed to DCFH at pH 7.0 with 0.01 N NaOH. The solution was put in
124 the dark for 30 min at room temperature and the chemical reactions was stopped by adding ice cold 0.1 M
125 PBS. Then, horse radish peroxidase (HRP, Sigma P8125) at 20U/ml was added to each sample. To
126 facilitate the comparison between a cellular and cell free system, the solutions were incubated at 37°C in
127 the dark. The fluorescence generated by the DCFH oxidation was measured using a microplate reader at
128 485 nm excitation and 530 nm emission after 120 min. Freshly diluted hydrogen peroxide (10µM) was
129 used as a positive control. The data were recorded as arbitrary fluorescence units. Two technical and three
130 biological replicates were performed.

131 *Isolation and exposure of primary mice hepatocytes to NPs*

132 Hepatocytes were isolated from C57/6J mice by a collagenase (Roche Diagnostics, Barcelona, Spain)
133 perfusion technique, as described previously [33]. Cells were seeded on fibronectin-coated dishes (3.5
134 µg/cm²) (2.5 x 10⁶ viable cells per plate) and cultured at 37 °C and 5% CO₂ as described by Palacios *et al.*
135 [34]. The culture medium was Ham's F-12/Leibovitz L-15 (1/1, v/v) supplemented with 2% newborn calf
136 serum, 2 mM L-glutamine, 5 mM glucose, 5 U/mL penicillin, 5 mg/mL streptomycin, 50 mg/L
137 gentamycin, 0.2% fatty acid-free bovine serum albumin (BSA), and 10 nM insulin. After 1 h of adhesion,
138 the medium was changed and the hepatocytes were exposed to different types of NPs for 48 h, frozen in
139 liquid nitrogen and stored at -80 °C. In this study, primary cultures of mouse hepatocytes were treated with
140 the previously described metal and metal oxide NPs (TiO₂, ZnO, CuO, and Ag-NPs) at 1 and 5 mg/L
141 concentrations for 48 h. The choice of the concentrations was based on a previous *in vitro* study of catfish
142 primary hepatocytes and human cells exposed to metal oxide NPs with some modifications [35]. All the
143 experiments were conducted in compliance with institutional guidelines, and the analyses were performed
144 on at least four biological replicates for each treatment (control included) unless specified otherwise.
145 Animal procedures were approved by the University of the Basque Country and Animal Care and Use
146 Committees.

147 *Cell viability assay*

148 The cytotoxicity of NPs was determined using standard MTT assay described previously with slightly
149 modifications [36]. Briefly, primary mouse hepatocyte cells were plated in two 96-well culture plates in
150 200 µl of culture medium at a density of 1 x 10⁵ cells/ml. After incubation for 24 h, NPs at concentrations

151 of 1 and 5 mg/L were added to respective cells. The cells were then cultivated for an additional 48 h with
152 NPs containing medium changed every day. On the third day, 20 μ l of tetrazolium dye MTT solution (5
153 mg/mL) was added to each well and was further incubated for 4 h. The supernatants were then removed
154 and 200 μ l of dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystal at 37 °C. The
155 absorbance was measured with a VICTOR3™ multi-labeled microplate reader (Perkinelmer Inc.,
156 Waltham, MA USA) at 560 nm. The assay was performed twice with three replicates for each sample in
157 each assay.

158 *Preparation of protein extracts*

159 Hepatocytes media was carefully discarded and cells pellets ($\sim 1.5 \times 10^6$ cells per sample) were re-
160 suspended in cell washing buffer solution (10mM Tris-base pH 8, 5mM of magnesium acetate) centrifuged
161 at 12,000 g at 4°C for 4 min for three times according to the manufacturer's instructions (GE Healthcare).
162 Later, hepatocytes were re-suspended in lysis buffer (2% ASB14, 8M urea, 5mM magnesium acetate,
163 20mM Tris-base pH 8.5)[37], left on ice for 10 min, and sonicated intermittently on ice until cells were
164 lysed. Cell debris was removed by centrifugation at 12,000 g at 4°C for 10 min while the supernatant was
165 transferred in new tubes followed by 20% of trichloroacetic acid (TCA) in cold acetone at -20°C overnight.

166 The protein precipitates were collected by centrifugation at 12,000 g for 5 min, and then the proteins were
167 solubilized again in lysis buffer. Cycles of intermittent sonication followed by centrifugation at 10,000 g
168 for 10 min were performed until all proteins were solubilized in the buffer and no evidence of precipitate
169 was observed. All these steps were carried at 4 °C. Before DIGE labeling, protein concentrations were
170 measured according to Bradford method [38].Bovine serum albumin was used as standard.

171 *Cy-Dye labeling and separation of proteins by 2DE*

172 Protein CyDye labeling and DIGE analysis were performed according to the manufacturer's instructions
173 (GE Healthcare). Samples containing 25 μ g of solubilized proteins were labeled by 200 pmol of
174 reconstitute CyDye. The quenched Cy3- and Cy5-labeled samples for each experimental sample were then
175 combined with the quenched Cy2-labeled pool internal standard. These samples were then quenched by the
176 addition of 1 μ L 10 mM lysine followed by incubation on ice for 10 min. The total proteins (75 μ g) were
177 mixed and denatured in sample buffer (7M urea, 2M thiourea, 2% ASB 14, 2% DTT, 2% IPG buffer (pH
178 3-10)), and then rehydrated with rehydration buffer (7M urea, 2M thiourea, 2% ASB 14, 0.2% DTT, 1%
179 IPG buffer (pH 3-10)) and trace amounts of bromophenol blue. A final volume of 200 μ l of sample was
180 then distributed evenly along IPG strip pH 3–10NL, 11 cm, covered by mineral oil and passively
181 rehydrated for at least 12 h in dark conditions. Isoelectric focusing was performed on a Protean IEF Cell

182 (Bio-Rad) at 20°C using wet wicks inserted between the IPG strips and the electrodes. The first dimension
183 was carried using the following program as recommended by the manufacturer's instructions (Bio-Rad):
184 rapid voltage slope at all the steps; step 1, 250 V for 15 min; step 2, 8000 V for 2.5 h, and step 3 at 8000 V
185 until 35000 Vh was reached. After focusing the strips were equilibrated for 15 min in equilibration buffer
186 (6 M urea, 0.375 M Tris, pH 8.8, 2% SDS, 20% glycerol) containing 2% DTT and then for 15 min in
187 equilibration buffer containing 2.5% iodoacetamide. The second dimension was carried out on
188 homogeneous 12.5% T Criterion precast gels (Bio-Rad, Hercules, CA) at 120 V for 2h using a Criterion
189 Cell (Bio-Rad). DIGE gels were fixed in 10% methanol and 7.5% acetic acid for 1h in the dark and washed
190 with bi-distilled water for 15 min before image acquisition. After image acquisition the gels were stained
191 by colloidal Coomassie blue staining for subsequent spot picking and protein identification.

192 *Image acquisition and analysis*

193 DIGE gels were scanned using FLA-5100 Fluorescence Image Analyzer (Fuji Medical, Stamford, CT)
194 according to manufacturer's recommendation. DIGE images (16 bit TIFF, 600 PMT) were analyzed by
195 REDFIN software (Ludesi, Malmö, Sweden, <http://www.ludesi.com>) for spot detection, spot quantification
196 and normalization, spot matching and statistical analysis. The comparison of test spot volumes (Cy3 or
197 Cy5 labelled) with the corresponding internal standard spot volume (Cy2 labeled) gave normalization for
198 each matched spot. This allows a satisfactory quantification and comparison of different gels. Differential
199 expression of proteins was defined on the basis of ≥ 1.5 -fold change between group averages and one-way
200 ANOVA $p \leq 0.05$.

201 *Protein identification by mass spectrometry*

202 Mass spectrometry analysis for protein identification was performed on nano-LC-MS/MS (Bruker
203 Daltonics, Bremen, Germany) after protein spot excision and trypsin in-gel digestion. Briefly,
204 differentially expressed spots excised proteins were treated with 25mM of NH_4HCO_3 in 50% of
205 acetonitrile (ACN) until complete de-staining, dried with 99.5% ACN, and digested with sequencing grade
206 modified trypsin in 25mM NH_4HCO_3 for 16 hours at 37°C. The peptides were extracted twice with 5%
207 formic acid (FA) in 50% ACN and dried in Speed Vac concentrator (THERMO SAVANT, Holbrook,
208 NY, USA). The fractions were desalted using C18 ZipTip (Millipore) following the manufacturer's
209 instructions and the nano-electrospray capillaries were loaded with 6 μl of peptide solutions in 50% ACN
210 in water with 0.1% FA. A 20 mm \times 100 μm pre column followed by a 100 mm \times 75 μm analytical column
211 both packed with reverse-phase C18 were used for separation at a flow rate of 300 nl/min. The gradient
212 buffers used were 0.1% formic acid in water (A) and 0.1% formic acid in 100% acetonitrile (B).
213 Separation was performed with a linear gradient for 60 min (100-0% sol. A in 60 min, 0-100% sol. B in 60

214 min). Automated online tandem MS analyses were performed when peptide ions were sequenced using
215 two alternating fragmentation techniques: collision induced dissociation (CID) and electron transfer
216 dissociation (ETD). The data obtained were analyzed by Bruker Daltonics DataAnalysis 3.4 and the
217 resulting MGF files were used to search for protein in Swissprot (*Mus musculus*) using Mascot Server
218 (2.3) (www.matrixscience.com). The search parameters allowed mass error up to 0.8 Da for MS data and
219 up to two missed trypsin cleavage. Peptide modifications searched for included carbamidomethyl (Cys) as
220 the only fixed modification, and up to two variable modifications from among the following: oxidation
221 (Met), acetyl (N-term), pyroglutamate (Gln) and Met-loss (N-term). Significance threshold in the
222 MASCOT searches was set as $p < 0.01$. Peptides were considered reliable if the MS/MS spectra had a
223 MASCOT score above 35 and an expect value below 0.01.

224 Molecular weight and pI of the identified proteins were calculated with the ExPASy compute pI/Mw tool
225 (http://www.expasy.ch/tools/pi_tool.html).

226 *Extraction, separation and quantification of lipids*

227 After quantification of the amount of cellular protein by the bicinchoninic acid method following
228 manufacturer (PIERCE) instructions, lipids were extracted from 2 mg of cellular protein following the
229 method of Folch *et al.* [39]. Briefly, eight volumes of chloroform/methanol/water (2:1:0.0075, v:v:v) were
230 added and the methanol phase was re-extracted with four volumes of the same mixture. The chloroform
231 phases were aspirated, combined, and washed with 1.5 ml of 0.88% KCl. Different species of lipids were
232 separated using a thin-layer chromatography system composed of six sequential mobile phases as
233 described by Ruiz and Ochoa [40]. Standard curves for all lipid classes were run in each plate. The lipid
234 spots were quantified as detailed previously [41] using Quantity One software (Bio-Rad). Analysis was
235 carried out at least twice per extract.

236 *Statistical analysis*

237 Statistical analysis was performed using GraphPad Prism version 5.02 (GraphPad Software, San Diego,
238 CA). Paired comparisons were made using Student's t-test while the comparison of multiple treatments to a
239 common control was performed using one-way analysis of variance (ANOVA) with Dunnett's test, and $p <$
240 0.05 was considered significant.

241

242 **3. Results**

243 *NPs characterization*

244 The results of NPs characterization in powder form and dispersed in the cell media are represented in
245 Table 1. Information about the properties of the NPs in powder form was obtained from the manufacturer.
246 NPs in the hepatocyte culture media showed agglomeration and/or aggregation. The NPs hydrodynamic
247 size was characterized using Dynamic light scattering (DLS) which showed, in general, a bimodal
248 distributions at concentrations 5 and 500 mg/L. The hydrodynamic size of CuO-NPs could not be obtained
249 at 5 mg/L due to high noise to signal ratio. Generally, a stable suspension has a zeta potential value higher
250 or lower than +/-30 mV (Malvern) and therefore none of the NPs were in stable suspension.

251

252 *NPs oxidative ability and impact in cell viability*

253 The oxidative ability of the metal and metal oxide NPs was investigated by cell-free dichlorofluorescein
254 (DCFH) assay using 5 and 1 mg/L after 2 h exposure (Figure 1A). Our results evidenced that only ZnO-
255 NPs and CuO-NPs at 5 mg/L had significant oxidative activity ($p < 0.01$) while Ag-NPs and TiO₂-USNPs at
256 5 mg/L showed a significantly low fluorescent intensity ($p < 0.01$), remarking their negligible oxidizing
257 activity. The cell viability has been assessed by MTT assay after NPs exposure for 48 h. Hepatocytes
258 exposed to low and high concentration of TiO₂-USNPs, and ZnO-NPs, and to low concentration of CuO-
259 and Ag-NPs did not show effects in the cell viability. However, the viability of the hepatocytes exposed to
260 high concentration of CuO-NPs and Ag-NPs significantly decreased by 50% compared to non-treated cells
261 (Figure 1B).

262

263 *Proteomic analysis of impact of NPs exposure*

264 Two dimensional DIGE (2D-DIGE) images of the protein extracts from hepatocytes (NPs treated and
265 untreated) were imported to REDFIN software that detected 998 spots per gel (Supplementary Figure 1)
266 evenly distributed along the whole range of pH (3-10) but more abundant between 24-150 kDa.
267 Comparisons between several groups control versus all treated or each treatment were taking in
268 consideration for the statistical analysis of the data. The comparison control versus all NPs treatments
269 revealed a total of 84 spots differentially expressed ($p < 0.05$, fold change ratio ≥ 1.5) (Figure 2A). In
270 particular exposure to CuO-NPs and Ag-NPs at 5 mg/L showed the largest number of modified proteins.
271 ZnO-NPs exposure showed similar number of differentially expressed proteins at both concentrations,
272 underlining a concentration-independent response. The TiO₂-USNPs exposures caused the least modified
273 protein profiles (Figure 2B). We found the highest number of unique spots at the high concentration
274 exposure for all NPs. However, the concentration-dependent response varied among the NPs studied. The

275 CuO-NPs and Ag-NPs exposures duplicated and triplicated respectively, the number of differentially
276 expressed spots from low to high concentration whereas a very low increase of concentration-dependent
277 response was observed at TiO₂-USNPs and ZnO-NPs exposures. The impact at the protein level of the NP
278 exposures was characterized by down-regulation. In hepatocytes exposed to Ag-NPs, most of the
279 differentially expressed proteins were down-regulated underlining the strongest effects on the proteome.
280 The changes in protein expression profile ($p < 0.05$, fold change ratio ≥ 2) caused by exposure to the studied
281 type and concentration of NPs were summarized in the supplementary material (Supplementary, Figure 1
282 and 2).

283

284 *Identification of differentially expressed proteins*

285 Considering the analytical method applied, 2D-DIGE, and the results showing a general response based on
286 down-regulation, many differentially expressed spots were under the expression level required for
287 identification. For those spots, additional trials were performed after pooling the same spot from all the
288 DIGE gels but unfortunately some excised and selected spots analyzed by mass spectrometry remained
289 still unidentified. The identified proteins were selected among the proteins differentially expressed ($p < 0.05$
290 and with fold change ≥ 1.5) and in common with at least two NPs exposures included the comparison
291 control versus all NPs treatments (Figure 3, Table 2). Most of the identified proteins were common among
292 all the exposures but some NPs had specific effect on the expression of unique proteins. The protein
293 (ID25) carbamoyl-phosphatase synthase (CSP1) was the most commonly differentially expressed protein
294 being up-regulated in CuO-NPs (5 mg/L), ZnO-NPs (5 and 1 mg/L) and Ag NP (5 mg/L). TiO₂-USNPs
295 caused the up-regulation ATP-Synthase and ETF protein subunit alpha while CuO-NPs (1 mg/L) caused
296 the down-regulation of ETF protein subunit beta as well as Tubulin beta-6 chain (ID497) at both
297 concentrations. ZnO-NPs caused the down-regulation of RNA helicase (Figure 3). Approximately 50% of
298 the identified proteins are localized in the specific organelles such as mitochondria (including matrix and
299 membrane) while the remaining proteins belong to cytoplasm and also with the exception of alpha-enolase
300 (ID49 and ID102) and guanine nucleotide-binding protein (G-Protein) subunit beta-2-like 1 (ID 572)
301 which can also be from cell membranes. The only nuclear protein identified was heterogeneous nuclear
302 ribonucleo-protein F (HNRPF) (ID222) (Table 2). The only protein with unclear subcellular localization
303 was helicase eIF4A (ID 273) which can be both in the nucleus and in the cytoplasm.

304

305 *Post-translational modifications*

306 The main post-translational modification found in numerous proteins was the oxidation of methionine
307 residues which causes small change of pI from the theoretical value (Table2). It is significantly in the
308 mitochondrial ATP synthase subunit alpha (ID209), (ATPA) that showed a big difference in pI from the
309 theoretical value (Table 2). However the sequence found by mass spectrometry (the pI value was 6.1),
310 which is close to that observed by 2DE, would match with the main chain of this protein without transit
311 peptide.

312

313 *Lipidomics*

314 Details on the lipid composition of hepatocytes from control and exposed to NPs at 5 mg/L are represented
315 in Figure 4. Interestingly, a significant decrease in the percentage of sphingomyelin (SM) was found in the
316 cells exposed to Ag-NPs ($p < 0.001$) but also exposed to TiO₂-USNPs ($p < 0.05$) (Figure 4A). CuO-NPS
317 exposure caused a decrease in the percentage of PI and PE (Figure 4A) which made the PC/PE ratio
318 decreased (Figure 4B), a predictor of altered membrane fluidity. In the cells exposed to Ag-NPs changes
319 in the total lipid quantities were observed with a significant increase of triacylglycerol (TG) cell content
320 (Figure 4C).

321

322 **4. Discussion**

323 The application of quantitative proteomics in combination with lipidomics can be a a useful method to
324 illustrate the effects of NPs in cell lines. In this study the effects of exposure to TiO₂-USNPs, ZnO-NPs,
325 CuO-NPs and Ag-NPs for 48 h were studied on primary mouse hepatocytes. After characterization of the
326 physicochemical properties of the NPs, their cytotoxicity was assessed followed by quantitative proteomic
327 and lipidomic analysis. Based on the cellular and molecular effects on the primary mouse hepatocytes, the
328 overall ranking of the impact of the NPs exposures is as follows: TiO₂<ZnO<Ag<CuO.

329 *Cytotoxicity of NPs*

330 TiO₂-USNPs (1-3 nm) used in this study were not cytotoxic (Figure 1B) at 1 or 5 mg/L. They did not
331 produce significant ROS (Figure 1A) and the insoluble nature of TiO₂-NPs has been shown in previous
332 studies [42]. Thus effects observed upon exposure to TiO₂-USNPs can be solely due to their size and direct
333 interactions with cellular components. ZnO-NPs exposures did not affect to the cellular viability, although
334 high concentration exposures could cause cytotoxicity in *in vitro* [15, 43]. However, despite lack of
335 toxicity, these NPs produced significant ROS (Figure 1A) and based on a previous study conducted by this
336 group, ZnO-NPs and CuO-NPs had the highest capacity of ions leakage [4]. Previous studies have

337 illustrated the importance of Zn ions in progression of alcoholic liver disease and hepatic lipid homeostasis
338 where it was shown that Zn supplementation reverses alcoholic steatosis by inhibiting oxidative stress [19].
339 Therefore the impact of ZnO-NPs exposure on the proteome could be related to the disruption of Zn
340 homeostasis and in combination with the increase of ROS levels cause cytotoxicity. As mentioned, similar
341 to ZnO-NPs, CuO-NPs produced ROS (figure 1A) and leaked ions. However the exposure to CuO-NPs
342 caused the most severe effects at the cellular and molecular level with significant reduction of cell
343 viability. The severe toxicity of CuO-NPs has been shown previously [23, 24]. Since the amount of ROS
344 produced alone could not be the unique cytotoxic input (as shown for ZnO-NPs), it is likely that the
345 released ions had actively contributed to the cytotoxicity. The importance of the intracellular solubility of
346 NPs has arisen from understanding the Trojan horse-type mechanism of intracellular dissolution and its
347 impact on the release of ions inside the cells leading to toxicity [44]. It has recently been reported that the
348 intracellular solubility of CuO-NPs has the most critical role on the cytotoxicity [45]. Another type of NPs
349 with great impact on the hepatocytes viability was Ag-NPs. These NPs however did not produce ROS.
350 Previous studies have shown the uptake of the Ag-NPs despite different pattern of agglomeration as well
351 as release of ions, both contributing to toxicity [46, 47].

352 *Global impact of the NPs exposure to hepatocytes*

353 The cellular impact of the NPs exposure was globally studied by combining proteomics and lipidomics.
354 The differentially expressed proteins identified were involved in lipid metabolism, electron transport chain,
355 structure of the cell, signaling, metabolism as well as nuclear proteins.

356 *Impact on lipids and fatty acid metabolism*

357 One of the common cellular responses observed was variation of the cellular lipids (i.e. CuO-NPs, Ag-NPs
358 and TiO₂-USNPs) and differential expression of proteins involved in fatty acid and lipid metabolism was
359 also observed. The lipidomic results showed a significant decrease of percentage of SM in the hepatocytes
360 exposed to TiO₂-USNPs at 5 mg/L, although the PC/PE and CL/PL values indicated that the membrane
361 fluidity was not affected (Figure 4). Lipid rafts, defined as cholesterol- and sphingolipid-enriched
362 membrane micro-domains, might be altered by TiO₂-USNPs exposure in plasma membrane, triggering
363 ROS release by enzymes localized in the membrane rafts. These ROS stimulate ceramide-releasing
364 enzymes (e.g. acid sphingomyelinase) which are responsible for converting SM into phosphorylcholine
365 and ceramide, increase the ceramide-enriched membrane platforms [48, 49]. It has been reported that
366 carbon-based NPs treatment in lung epithelial cells led to an increase of ceramides in lipid rafts [50]. This
367 feed-forward mechanism can justify the decrease of SM in the TiO₂-NPs exposure. The exposure to CuO-
368 NPs caused significant increase of the ratio PC/PE and a decrease percentage of some PE and PI as well as

369 increase in concentration of TG. The effect of Cu on the cellular lipid droplets has been shown previously
370 [4]. Damage of the cellular plasma membrane has been shown to be one of the primary events in heavy
371 metal (Cu and Zn) toxicity in plants [51, 52]. Previous studies have shown heavy metal stress increased
372 PE, decreased PI, and PG [53], although the decrease in PE values observed in our study has also been
373 shown in other studies [54]. Cu deficiency has been shown to increase *in vivo* hepatic synthesis of fatty
374 acids, TG, and PL in rats [55]. Therefore the decrease of this lipid class could be correlated to Cu
375 overload. Cells exposed to Ag-NPs had decrease in SM but increase in the number of TG and total lipids.
376 The increase in total lipids due to exposure to Ag-NPs has been observed previously [56]. Proteomic data
377 in this study showed that mitochondrial HMG-CoA synthase was down-regulated in the cells exposed to
378 TiO₂-USNPs at 1 mg/L and to CuO-NPs at 5 mg/L. This enzyme has a key function in regulating the
379 ketogenesis, pathway involved in the biosynthesis of ketones bodies, metabolic fuel during starvation [57].
380 Another mitochondrial protein involved in lipid and fatty acid metabolism, 3-oxoacyl-coA thiolase was up-
381 regulated in CuO-NPs, and particularly, in Ag-NPs treatment. This enzyme catalyzes the last step in
382 mitochondrial and peroxisomal β -oxidation [58]. The increase the total lipids and TAG observed in cells
383 exposed to Ag-NPs could have led to an increase in 3-oxoacyl-coA thiolase involved in beta oxidation and
384 lipid metabolism.

385 *Impact on proteins involved in electron transport chain*

386 The differential expression of protein involved in the electron transport chain could reflect the increase in
387 cellular energy demand upon exposure to NPs. CuO-NPs at both concentrations, TiO₂-USNPs (1 mg/L)
388 and ZnO-NPs (5mg/L) affected these proteins. However proteins involved in this pathway were mostly
389 affecting to one type of NPs exposure. The up-regulation of ATP synthase was only found in the
390 hepatocytes exposed to TiO₂-USNPs. This protein is one of the most abundant proteins in the inner
391 mitochondrial membrane which is involved in H⁺ transport at the mitochondrial membrane and provides
392 ATP [59, 60]. Another protein uniquely affected by TiO₂-USNP exposure was ETF subunit alpha which
393 are heterodimers and function as electron shuttles between primary flavoprotein dehydrogenases involved
394 in mitochondrial fatty acid and amino acid catabolism and the membrane-bound electron transfer
395 flavoproteins ubiquinone oxidoreductase [61]. In cells exposed to CuO-NPs a remarkable reduction of the
396 expression of ETFs subunit beta was detected. An imbalance of these “housekeeping” proteins can have
397 serious repercussions especially in the oxidation of fatty acids [62]. ZnO-NPs and CuO-NPs at 5 mg/L
398 evidenced an increase of ROS and the up-regulation of the subunit 1 of cytochrome b-c1 complex or
399 Complex III, protein. Complex III is the major ROS production site among all mitochondrial electron
400 transport chain complexes, and it is the only complex that generates $\cdot\text{O}_2$ in the mitochondrial inter-

401 membrane space [63, 64]. Xia et al.[65] observed mitochondrial contribution to ZnO-NPs-induced ROS
402 production, through the ultra-structural, and thereby membrane potential changes in this organelle. They
403 also suggest that the release of Zn ions from NPs may exert extra-mitochondrial effects contributing to
404 ROS generation, including NO production and generation of peroxynitrite (ONOO⁻). We have previously
405 shown the significant release of Zn ions from ZnO-NPs [4].

406 *Impact on proteins from urea cycle*

407 CPS1, a mitochondrial enzyme involved in ATP-dependent formation of carbamoyl phosphate from
408 glutamine or ammonia and bicarbonate in the first step of the urea cycle. This protein was over-expressed
409 in the cells exposed to ZnO-NPs (5 and 1 mg/L), Ag-NPs (5 mg/L) and CuO-NPs (5 mg/L). Generally, an
410 increase of CPS1 expression has been observed in the case of liver damage or during acute hepatitis, as
411 disorders induced by oxidative stress [66] and it is one of the main potential toxicity markers found in rat
412 liver cells [67]. Previous studies have reported the effect of Zn in urea cycle and increased of activities of
413 CPS1 in the liver of zinc-deficient rats[68]. It is interesting that the possible Zn ions released by the NPs in
414 this study have caused the up regulation of CPS1.

415 *Impact on nuclear proteins*

416 ZnO-NPs were the only NPs that affected both RNA helicase, and hnRNP. It has been described how
417 ultrafine NPs could affect the expression of nuclear proteins [69]. We observed that ZnO-NPs exposure
418 specifically caused the down-regulation of the ATP-dependent RNA helicase (eIF4) which plays
419 important roles in the unwinding and remodeling of structured RNA as well as virtually all aspects of
420 nucleic acid metabolism, and regulation, possibly enhancing the biosynthesis of altered proteins [70].
421 Previous study has shown that down-regulation in helicase is associated with cell cycle perturbations and
422 in apoptosis which in this case might be an indication of oxidative stress and early stages of apoptosis
423 experienced by the cells [71].

424 Among all identified differentially expressed proteins, only one nuclear protein, the hnRNP F, was affected
425 by NPs treatment and was down-regulated by treatment with Ag-NPs and up-regulated by ZnO-NPs, and
426 CuO-NPs treatment. The hnRNP complexes are known to play a role in the regulation of the splicing
427 events but they have also been shown to function in the regulation of cell proliferation. Overexpression of
428 hnRNP F has been shown to promote cell proliferation while reverse effect was observed upon knockdown
429 of hnRNP F [72]. Disruption in this protein therefore could lead to genotoxicity as well as disruption in
430 cell proliferation. It is possible that the cytotoxicity observed in Ag-NPs exposed cells was due to down-
431 regulation of this protein.

432 *Impact on structural proteins*

433 Another modified protein in hepatocytes exposed to ZnO-NPs or Ag-NPs (at 5 mg/L) was β -tubulin IV
434 (TBB4B) which was down-regulated especially for the Ag-NPs treatment. This protein is the main
435 constituent of microtubules, key components of the cytoskeleton of eukaryotic cells and has an important
436 role in various cellular functions such as intracellular migration and transport, cell shape maintenance,
437 polarity, and cell signaling. Previous *in vitro* studies showed that metal and metal oxide NPs can directly
438 bind functional groups of microtubules [73, 74]. In particular, Ag-NPs interacting with tubulin in
439 correspondence of -SH residue may be responsible of ineffective mitotic spindle function [75][76].
440 Tubulin is the first non-receptor protein found to be phosphorylated by G-protein receptor kinases [77].
441 Interestingly both ZnO-NPs (5mg/L) and Ag-NPs (1 mg/L) induced an increase of G-protein expression
442 involved in many cellular signaling pathways, including the ubiquitination and proteasome-mediated
443 degradation [70]. The isotype of β -tubulin (TBB6) was significantly up-regulated in hepatocytes exposed
444 to CuO-NPs at 5 and 1 mg/L which can contribute to an adaptation to oxidative stress conditions and drug
445 resistance [78]. A compensatory mechanism from the hepatocytes exposed to CuO-NPs might occur to
446 overwhelm the structural damages in the cytoskeleton, especially in the case of the highest concentration.
447 HSPs function in important intracellular tasks such as protein folding and transport acting as chaperones
448 under stress to prevent protein denaturation and loss of function [79]. HSP60 is a mitochondrial expressed
449 stress protein that can be translocated to the cytosol and, later, transported to the cell surface. The HSP60
450 stress response is correlated with apoptosis and exacerbation of the disease state [80]. This protein was
451 over-expressed in the two cytotoxic NPs i.e. Ag-NPs and CuO-NPs illustrating the apoptotic response of
452 the cells.

453

454 *Impact on cellular metabolism*

455 Mitochondrial ALDH (ID34), and Alpha-enolase (ID49 or ID102) were found up-regulated in NPs
456 treatments and can be considered as an early cellular defense response to general stress conditions. ALDH
457 catalyzes the oxidation of various aliphatic and aromatic aldehydes to the corresponding acids and is in
458 cellular defenses against toxic aldehydes [81]. Also it has been shown that mitochondria-located alpha-
459 enolase stabilizes mitochondrial membrane and its' displacement may involve in activation of the
460 intrinsic cell death pathway [82].

461

462 **5. Concluding Remarks**

463 Characterization of the NPs, classical toxicity assays and quantitative proteomics in combination with
464 lipidomics could provide a detailed overview of the effects of NPs on primary hepatocytes. Most proteins
465 identified to be differentially expressed were in common for the different NPs exposures and were
466 involved in lipid metabolism, electron transport chain, cellular structure, metabolism, signaling as well
467 nuclear proteins. CuO-NPs produced ROS, were cytotoxic, affected the PL and caused the down-
468 regulation of ETF protein beta. Ag-NPs did not produce ROS but were cytotoxic, affected the SM as well
469 as increasing total cellular lipids and TG. ZnO-NPs despite producing significant ROS were not cytotoxic
470 and did not affect the cellular lipids but affected the RNA helicase. TiO₂-USNP did not produce ROS,
471 were not cytotoxic yet affected the SM and affected ATP-synthase as well as ETF protein alpha. This work
472 showed that some of our gaps for understanding the NP impact at the cellular level could be filled by
473 combining data from alterations on lipidomic profiles with proteomic profiles. This OMICs methods or
474 any extension to other OMICs methodologies would lead to a system biology understanding of NP impact
475 and possible adverse outcome pathway.

476

477 **6. Supplementary material**

478 **S1: Supplementary Figure 1:** Representative 2D-DIGE proteins from hepatocytes exposed to NPs. A
479 total of 998 spots were detected by REDFIN software.

480 **S2: Supplementary Figure 2:** Proteins up- and down-regulated by NPs along with fold change (F.C.).

481 **S3: Table lipidomics:** TG, triacylglycerol; CE, cholesteryl ester; FC, free cholesterol; PC,
482 phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; PI, phosphatidylinositol; SM,
483 sphingomyelin. Total lipid quantities correspond to the summation of all measured lipid species, which are
484 expressed as the percentage of the summation. Total phospholipid quantities correspond to the summation
485 of PC, PE, SM, PS and PI and total cholesterol to the summation of FC and CE. Data are expressed as the
486 mean \pm SEM and correspond to the results obtained using 5 mg/L concentration of NPs in the culture
487 medium. Control vs. treated: *P \leq 0.05, ***P \leq 0.001.

488

489 **Acknowledgements**

490 This work was supported by grants from the Swedish Research Council-Natural Science (VR-N) (SC),
491 Carl Trygger Foundation (SC), VINNOVA-Vinnmer program (SC), Oscar Lilli Lamms Minne Foundation
492 (SC), Långmanska kulturfonden (SC), Lars Hiertas Minne foundation (SC), IKERBASQUE, Basque
493 Foundation for science (SC), Ångpanneförening foundation (SC). We would like to thank Dr. Itsaso
494 Garcia-Arcos for her help with our preliminary experiments with cell cultures, to Mr. Bengt-Arne

495 Fredriksson for the TEM analysis, Jacob Kuruvilla, Christine Gallampois for their helpful suggestions on
496 the elaboration of MS data.

497

498

499 **References**

500

501 [1] L. Mazzola, *Nat Biotech*, 21 (2003) 1137-1143.

502 [2] C.N. Lok, C.M. Ho, R. Chen, Q.Y. He, W.Y. Yu, H. Sun, P.K. Tam, J.F. Chiu, C.M. Che, *Journal of*
503 *proteome research*, 5 (2006) 916-924. 10.1021/pr0504079: 10.1021/pr0504079

504 [3] E.J. Park, J. Yi, Y. Kim, K. Choi, K. Park, *Toxicology in vitro : an international journal published in*
505 *association with BIBRA*, 24 (2010) 872-878. 10.1016/j.tiv.2009.12.001: 10.1016/j.tiv.2009.12.001

506 [4] N. Bayat, K. Rajapakse, R. Marinsek-Logar, D. Drobne, S. Cristobal, *Nanotoxicology*, 8 (2014) 363-
507 373. doi:10.3109/17435390.2013.788748: doi:10.3109/17435390.2013.788748

508 [5] B.K. Gaiser, S. Hirn, A. Kermanizadeh, N. Kanase, K. Fytianos, A. Wenk, N. Haberl, A. Brunelli,
509 W.G. Kreyling, V. Stone, *Toxicological Sciences*, 131 (2013) 537-547. 10.1093/toxsci/kfs306:
510 10.1093/toxsci/kfs306

511 [6] S. Hirn, M. Semmler-Behnke, C. Schleh, A. Wenk, J. Lipka, M. Schäffler, S. Takenaka, W. Möller, G.
512 Schmid, U. Simon, W.G. Kreyling, *European Journal of Pharmaceutics and Biopharmaceutics*, 77 (2011)
513 407-416. <http://dx.doi.org/10.1016/j.ejpb.2010.12.029>: <http://dx.doi.org/10.1016/j.ejpb.2010.12.029>

514 [7] C. Schleh, M. Semmler-Behnke, J. Lipka, A. Wenk, S. Hirn, M. Schäffler, G. Schmid, U. Simon, W.G.
515 Kreyling, *Nanotoxicology*, 6 (2012) 36-46. doi:10.3109/17435390.2011.552811:
516 doi:10.3109/17435390.2011.552811

517 [8] N. Serpone, A. Salinaro, A.V. Emeline, S. Horikoshi, H. Hidaka, J. Zhao, *Photochemical &*
518 *photobiological sciences : Official journal of the European Photochemistry Association and the European*
519 *Society for Photobiology*, 1 (2002) 970-981.

520 [9] N. Ambalavanan, A. Stanishevsky, A. Bulger, B.A. Halloran, C. Steele, Y. Vohra, S. Matalon,
521 *American Journal of Physiology - Lung Cellular and Molecular Physiology*, (2012).
522 10.1152/ajplung.00013.2012: 10.1152/ajplung.00013.2012

523 [10] C.K. Kim, T. Kim, I.-Y. Choi, M. Soh, D. Kim, Y.-J. Kim, H. Jang, H.-S. Yang, J.Y. Kim, H.-K.
524 Park, S.P. Park, S. Park, T. Yu, B.-W. Yoon, S.-H. Lee, T. Hyeon, *Angewandte Chemie International*
525 *Edition*, 51 (2012) 11039-11043. 10.1002/anie.201203780: 10.1002/anie.201203780

526 [11] H. Soo Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, J.V. Frangioni,
527 *Nat Biotech*, 25 (2007) 1165-1170.

528 http://www.nature.com/nbt/journal/v25/n10/suppinfo/nbt1340_S1.html:

529 http://www.nature.com/nbt/journal/v25/n10/suppinfo/nbt1340_S1.html

530 [12] B.H. Kim, N. Lee, H. Kim, K. An, Y.I. Park, Y. Choi, K. Shin, Y. Lee, S.G. Kwon, H.B. Na, J.-G.
531 Park, T.-Y. Ahn, Y.-W. Kim, W.K. Moon, S.H. Choi, T. Hyeon, *Journal of the American Chemical*
532 *Society*, 133 (2011) 12624-12631. 10.1021/ja203340u: 10.1021/ja203340u

533 [13] L. Shang, S. Dong, G.U. Nienhaus, *Nano Today*, 6 (2011) 401-418.

534 <http://dx.doi.org/10.1016/j.nantod.2011.06.004>: <http://dx.doi.org/10.1016/j.nantod.2011.06.004>

- 535 [14] K. Huang, H. Ma, J. Liu, S. Huo, A. Kumar, T. Wei, X. Zhang, S. Jin, Y. Gan, P.C. Wang, S. He, X.
536 Zhang, X.-J. Liang, *ACS Nano*, 6 (2012) 4483-4493. 10.1021/nn301282m: 10.1021/nn301282m
- 537 [15] Y. Wang, W.G. Aker, H.M. Hwang, C.G. Yedjou, H. Yu, P.B. Tchounwou, *The Science of the total*
538 *environment*, 409 (2011) 4753-4762. 10.1016/j.scitotenv.2011.07.039: 10.1016/j.scitotenv.2011.07.039
- 539 [16] M. Osmond-McLeod, R. Osmond, Y. Oytam, M. McCall, B. Feltis, A. Mackay-Sim, S. Wood, A.
540 Cook, *Particle and fibre toxicology*, 10 (2013) 54.
- 541 [17] Y.-Y. Kao, Y.-C. Chen, T.-J. Cheng, Y.-M. Chiung, P.-S. Liu, *Toxicological Sciences*, 125 (2012)
542 462-472. 10.1093/toxsci/kfr319: 10.1093/toxsci/kfr319
- 543 [18] T. Turney, M. Duriska, V. Jayaratne, A. Elbaz, S. O'Keefe, A. Hastings, T. Piva, P. Wright, B. Feltis,
544 *Chem Res Toxicol*, 25 (2012) 2057 - 2066.
- 545 [19] X. Kang, W. Zhong, J. Liu, Z. Song, C.J. McClain, J. Kang, Z. Zhou, *Hepatology*, 50 (2009) 1241-
546 1250.
- 547 [20] M.K. Mohammad, Z. Zhou, M. Cave, A. Barve, C.J. McClain, *Nutrition in clinical practice : official*
548 *publication of the American Society for Parenteral and Enteral Nutrition*, 27 (2012) 8-20.
549 10.1177/0884533611433534: 10.1177/0884533611433534
- 550 [21] P.T. Leung, Y. Wang, S.S. Mak, W.C. Ng, K.M. Leung, *Aquat. Toxicol.*, 105 (2011) 49-61.
551 10.1016/j.aquatox.2011.05.010: 10.1016/j.aquatox.2011.05.010
- 552 [22] B. Halliwell, J.M. Gutteridge, *Methods in enzymology*, 186 (1990) 1-85.
- 553 [23] M. Cuillel, M. Chevallet, P. Charbonnier, C. Fauquant, I. Pignot-Paintrand, J. Arnaud, D. Cassio, I.
554 Michaud-Soret, E. Mintz, *Nanoscale*, 6 (2014) 1707-1715. 10.1039/C3NR05041F: 10.1039/C3NR05041F
- 555 [24] M.A. Siddiqui, H.A. Alhadlaq, J. Ahmad, A.A. Al-Khedhairi, J. Musarrat, M. Ahamed, *PLoS ONE*, 8
556 (2013) e69534. 10.1371/journal.pone.0069534: 10.1371/journal.pone.0069534
- 557 [25] M. Mortimer, K. Kasemets, M. Vodovnik, R. Marinsek-Logar, A. Kahru, *Environmental science &*
558 *technology*, 45 (2011) 6617-6624. 10.1021/es201524q: 10.1021/es201524q
- 559 [26] J.S. Kim, E. Kuk, K.N. Yu, J.-H. Kim, S.J. Park, H.J. Lee, S.H. Kim, Y.K. Park, Y.H. Park, C.-Y.
560 Hwang, Y.-K. Kim, Y.-S. Lee, D.H. Jeong, M.-H. Cho, *Nanomedicine: Nanotechnology, Biology and*
561 *Medicine*, 3 (2007) 95-101.
- 562 [27] T.M. Benn, P. Westerhoff, *Environmental science & technology*, 42 (2008) 4133-4139.
563 10.1021/es7032718: 10.1021/es7032718
- 564 [28] M. Horie, H. Kato, K. Fujita, S. Endoh, H. Iwahashi, *Chemical research in toxicology*, 25 (2012) 605-
565 619. 10.1021/tx200470e: 10.1021/tx200470e
- 566 [29] A. Massarsky, J. Labarre, V.L. Trudeau, T.W. Moon, *Aquatic toxicology*, 147 (2014) 68-75.
567 <http://dx.doi.org/10.1016/j.aquatox.2013.11.026>: <http://dx.doi.org/10.1016/j.aquatox.2013.11.026>
- 568 [30] A. Albanese, P.S. Tang, W.C. Chan, *Annual review of biomedical engineering*, 14 (2012) 1-16.
569 10.1146/annurev-bioeng-071811-150124: 10.1146/annurev-bioeng-071811-150124
- 570 [31] *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, (2014).
- 571 [32] L. Foucaud, M.R. Wilson, D.M. Brown, V. Stone, *Toxicology letters*, 174 (2007) 1-9.
572 10.1016/j.toxlet.2007.08.001: 10.1016/j.toxlet.2007.08.001
- 573 [33] E. Isusi, P. Aspichueta, M. Liza, M.L. Hernandez, C. Diaz, G. Hernandez, M.J. Martinez, B. Ochoa,
574 *Atherosclerosis*, 153 (2000) 283-294.

575 [34] L. Palacios, B. Ochoa, M.J. Gomez-Lechon, J.V. Castell, O. Fresnedo, *Biochimica et biophysica acta*,
576 1761 (2006) 698-708. 10.1016/j.bbaliip.2006.05.005: 10.1016/j.bbaliip.2006.05.005

577 [35] Z. Wang, N. Li, J. Zhao, J.C. White, P. Qu, B. Xing, *Chemical research in toxicology*, 25 (2012)
578 1512-1521. 10.1021/tx3002093: 10.1021/tx3002093

579 [36] J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, J.B. Mitchell, *Cancer research*, 47 (1987)
580 943-946.

581 [37] J.E. Swatton, S. Prabakaran, N.A. Karp, K.S. Lilley, S. Bahn, *Molecular psychiatry*, 9 (2004) 128-
582 143. 10.1038/sj.mp.4001475: 10.1038/sj.mp.4001475

583 [38] M.M. Bradford, *Analytical biochemistry*, 72 (1976) 248-254.

584 [39] J. Folch, M. Lees, G.H. Sloane Stanley, *J. Biol. Chem.*, 226 (1957) 497-509.

585 [40] J.I. Ruiz, B. Ochoa, *J. Lipid Res.*, 38 (1997) 1482-1489.

586 [41] I. Garcia-Arcos, P. Gonzalez-Kother, P. Aspichueta, Y. Rueda, B. Ochoa, O. Fresnedo, *Lipids*, 45
587 (2010) 1101-1108. 10.1007/s11745-010-3492-2: 10.1007/s11745-010-3492-2

588 [42] S. Pakrashi, N. Jain, S. Dalai, J. Jayakumar, P.T. Chandrasekaran, A.M. Raichur, N. Chandrasekaran,
589 A. Mukherjee, *PLoS ONE*, 9 (2014) e87789. 10.1371/journal.pone.0087789:
590 10.1371/journal.pone.0087789

591 [43] J.X. Yu, T.H. Li, *Cell & bioscience*, 1 (2011) 19. 10.1186/2045-3701-1-19: 10.1186/2045-3701-1-19

592 [44] L.K. Limbach, P. Wick, P. Manser, R.N. Grass, A. Bruinink, W.J. Stark, *Environ. Sci. Technol.*, 41
593 (2007) 4158-4163.

594 [45] A.M. Studer, L.K. Limbach, L. Van Duc, F. Krumeich, E.K. Athanassiou, L.C. Gerber, H. Moch,
595 W.J. Stark, *Toxicology letters*, 197 (2010) 169-174. 10.1016/j.toxlet.2010.05.012:
596 10.1016/j.toxlet.2010.05.012

597 [46] A.R. Gliga, S. Skoglund, I.O. Wallinder, B.F.a.H.L. Karlsson, *Particle and fibre toxicology*, 11
598 (2014).

599 [47] B. Fadeel, N. Feliu, C. Vogt, A.M. Abdelmonem, W.J. Parak, *Wiley Interdisciplinary Reviews:*
600 *Nanomedicine and Nanobiotechnology*, 5 (2013) 111-129. 10.1002/wnan.1206: 10.1002/wnan.1206

601 [48] C.A. Dumitru, Y. Zhang, X. Li, E. Gulbins, *Antioxidants & redox signaling*, 9 (2007) 1535-1540.
602 10.1089/ars.2007.1692: 10.1089/ars.2007.1692

603 [49] A. Soloviev, E.M. Schwarz, M. Darowish, R.J. O'Keefe, *Journal of orthopaedic research : official*
604 *publication of the Orthopaedic Research Society*, 23 (2005) 1258-1265.
605 10.1016/j.orthres.2005.03.019.1100230604: 10.1016/j.orthres.2005.03.019.1100230604

606 [50] H. Peuschel, U. Sydlik, S. Grether-Beck, I. Felsner, D. Stockmann, S. Jakob, M. Kroker, J. Haendeler,
607 M. Gotic, C. Bieschke, J. Krutmann, K. Unfried, *Part Fibre Toxicol*, 9 (2012) 48. 10.1186/1743-8977-9-
608 48: 10.1186/1743-8977-9-48

609 [51] M. Janicka-Russak, K. Kabała, M. Burzyński, G. Kłobus, *Journal of Experimental Botany*, 59 (2008)
610 3721-3728. 10.1093/jxb/ern219: 10.1093/jxb/ern219

611 [52] J. Harwood, *Recent Environmental Concerns and Lipid Metabolism*, in: J.-C. Kader, P. Mazliak
612 (Eds.) *Plant Lipid Metabolism*, Springer Netherlands, 1995, pp. 361-368.

613 [53] Amal Ahmed Morsy, K.H.A. Salama, H.A. Kamel, M.M.F. Mansour, *EurAsian Journal of*
614 *BioSciences*, 6 (2012) 1-10.

- 615 [54] J. Zhang, H. Tang, H. Sun, S. Xu, *Dongbei Nongye Daxue Xuebao*, 42 (2011) 91-94.
- 616 [55] A.A. Al-Othman, F. Rosenstein, K.Y. Lei, *Experimental Biology and Medicine*, 204 (1993) 97-103.
617 10.3181/00379727-204-43640: 10.3181/00379727-204-43640
- 618 [56] S.M. Ouda, *Research Journal of Microbiology*, 9 (2014) 34-42.
- 619 [57] N. Shafqat, A. Turnbull, J. Zschocke, U. Oppermann, W.W. Yue, *Journal of molecular biology*, 398
620 (2010) 497-506. 10.1016/j.jmb.2010.03.034: 10.1016/j.jmb.2010.03.034
- 621 [58] B. Middleton, *The Biochemical journal*, 132 (1973) 717-730.
- 622 [59] S. Rexroth, A. Poetsch, M. Rogner, A. Hamann, A. Werner, H.D. Osiewacz, E.R. Schafer, H. Seelert,
623 N.A. Dencher, *Biochimica et biophysica acta*, 1817 (2012) 381-387. 10.1016/j.bbabo.2011.11.006:
624 10.1016/j.bbabo.2011.11.006
- 625 [60] D. Degli Esposti, J. Hamelin, N. Bosselut, R. Saffroy, M. Sebah, A. Pommier, C. Martel, A.
626 Lemoine, *Biochemistry research international*, 2012 (2012) 387626. 10.1155/2012/387626:
627 10.1155/2012/387626
- 628 [61] F.L. Crane, H. Beinert, *The Journal of biological chemistry*, 218 (1956) 717-731.
- 629 [62] M. Weidenhaupt, P. Rossi, C. Beck, H.M. Fischer, H. Hennecke, *Archives of microbiology*, 165
630 (1996) 169-178.
- 631 [63] J.F. Turrens, A. Boveris, *Biochem. J.*, 191 (1980) 421-427.
- 632 [64] C. He, S. Murthy, M.L. McCormick, D.R. Spitz, A.J. Ryan, A.B. Carter, *J. Biol. Chem.*, 286 (2011)
633 15597-15607. 10.1074/jbc.M110.187377: 10.1074/jbc.M110.187377
- 634 [65] T. Xia, M. Kovoichich, M. Liang, L. Madler, B. Gilbert, H. Shi, J.I. Yeh, J.I. Zink, A.E. Nel, *ACS*
635 *Nano*, 2 (2008) 2121-2134. 10.1021/nn800511k: 10.1021/nn800511k
- 636 [66] Y. Takami, H. Uto, T. Tamai, Y. Sato, Y. Ishida, H. Morinaga, Y. Sakakibara, A. Moriuchi, M.
637 Oketani, A. Ido, T. Nakajima, T. Okanou, H. Tsubouchi, *Hepatology research : the official journal of the*
638 *Japan Society of Hepatology*, 40 (2010) 438-445. 10.1111/j.1872-034X.2009.00615.x: 10.1111/j.1872-
639 034X.2009.00615.x
- 640 [67] B. Thome-Kromer, I. Bonk, M. Klatt, G. Nebrich, M. Taufmann, S. Bryant, U. Wacker, A. Kopke,
641 *Proteomics*, 3 (2003) 1835-1862. 10.1002/pmic.200300552: 10.1002/pmic.200300552
- 642 [68] Z.T. Cossack, A.S. Prasad, *Nutrition Research*, 7 (1987) 1161-1167. [http://dx.doi.org/10.1016/S0271-](http://dx.doi.org/10.1016/S0271-5317(87)80041-6)
643 [5317\(87\)80041-6](http://dx.doi.org/10.1016/S0271-5317(87)80041-6): [http://dx.doi.org/10.1016/S0271-5317\(87\)80041-6](http://dx.doi.org/10.1016/S0271-5317(87)80041-6)
- 644 [69] Y. Gao, N.V. Gopee, P.C. Howard, L.R. Yu, *Journal of proteomics*, 74 (2011) 2745-2759.
645 10.1016/j.jprot.2011.08.009: 10.1016/j.jprot.2011.08.009
- 646 [70] K.H. Moon, B.L. Hood, P. Mukhopadhyay, M. Rajesh, M.A. Abdelmegeed, Y.I. Kwon, T.P. Conrads,
647 T.D. Veenstra, B.J. Song, P. Pacher, *Gastroenterology*, 135 (2008) 1344-1357.
648 10.1053/j.gastro.2008.06.048: 10.1053/j.gastro.2008.06.048
- 649 [71] R.J. Szczesny, H. Obriot, A. Paczkowska, R. Jedrzejczak, A. Dmochowska, E. Bartnik, P.
650 Formstecher, R. Polakowska, P.P. Stepien, *Biology of the cell / under the auspices of the European Cell*
651 *Biology Organization*, 99 (2007) 323-332. 10.1042/bc20060108: 10.1042/bc20060108
- 652 [72] E.T.H. Goh, O.E. Pardo, N. Michael, A. Niewiarowski, N. Totty, D. Volkova, I.R. Tsaneva, M.J.
653 Seckl, I. Gout, *Journal of Biological Chemistry*, 285 (2010) 17065-17076. 10.1074/jbc.M109.078782:
654 10.1074/jbc.M109.078782
- 655 [73] X. Wu, Y. Tan, H. Mao, M. Zhang, *Int. J. Nanomedicine*, 5 (2010) 385-399.

656 [74] J.C. Zhou, X.H. Wang, M. Xue, Z. Xu, T. Hamasaki, Y. Yang, K. Wang, B. Dunn, *Materials Science*
657 *& Engineering C-Materials for Biological Applications*, 30 (2010) 20-26. DOI
658 10.1016/j.msec.2009.08.003: DOI 10.1016/j.msec.2009.08.003

659 [75] R. Kuriyama, H. Sakai, *Journal of biochemistry*, 76 (1974) 651-654.

660 [76] C.M. Rico, S. Majumdar, M. Duarte-Gardea, J.R. Peralta-Videa, J.L. Gardea-Torresdey, *Journal of*
661 *agricultural and food chemistry*, 59 (2011) 3485-3498. 10.1021/jf104517j: 10.1021/jf104517j

662 [77] N. Yoshida, K. Haga, T. Haga, *European journal of biochemistry / FEBS*, 270 (2003) 1154-1163.

663 [78] L. Cicchillitti, R. Penci, M. Di Michele, F. Filippetti, D. Rotilio, M.B. Donati, G. Scambia, C. Ferlini,
664 *Molecular cancer therapeutics*, 7 (2008) 2070-2079. 10.1158/1535-7163.MCT-07-2370: 10.1158/1535-
665 7163.MCT-07-2370

666 [79] R. Milkman, *JGP*, 45 (1962) 777-799.

667 [80] G. Pfister, C.M. Stroh, H. Perschinka, M. Kind, M. Knoflach, P. Hinterdorfer, G. Wick, *Journal of*
668 *Cell Science*, 118 (2005) 1587-1594. 10.1242/jcs.02292: 10.1242/jcs.02292

669 [81] K.-H. Lee, H.-S. Kim, H.-S. Jeong, Y.-S. Lee, *Biochemical and Biophysical Research*
670 *Communications*, 298 (2002) 216-224. [http://dx.doi.org/10.1016/S0006-291X\(02\)02423-3](http://dx.doi.org/10.1016/S0006-291X(02)02423-3):
671 [http://dx.doi.org/10.1016/S0006-291X\(02\)02423-3](http://dx.doi.org/10.1016/S0006-291X(02)02423-3)

672 [82] S. Gao, H. Li, Y. Cai, J.-t. Ye, Z.-p. Liu, J. Lu, X.-y. Huang, X.-j. Feng, H. Gao, S.-r. Chen, M. Li, P.-
673 q. Liu, *Arch Biochem Biophys*, 542 (2014) 46-55. <http://dx.doi.org/10.1016/j.abb.2013.12.008>:
674 <http://dx.doi.org/10.1016/j.abb.2013.12.008>


675
676
677

678 **Figures**

679 **Figure 1:** A) Oxidative potential assay. Fluorescence intensity [arbitrary units (a.u.)] of the NPs after
680 incubation with DCFH for 2 h at 37°C. Values are the mean ± SEM from three experiments. For each
681 treatment, two concentrations were used 1 and 5 *** p < 0.001. B) MTT assay for estimation of cell
682 viability, expressed as absorbance at 560 nm. *p< 0.01 and *p<0.001.

683

684



685

686


687 **Figure 2:** A) Differentially expressed proteins comparing control (untreated hepatocytes) versus each NPs
 688 exposure and B) Venn diagram representing differentially proteins among the exposures. The protein
 689 expression modification was considered significant for $p < 0.05$ and fold change ratio ≥ 1.5 .

690

A

Control vs Treated	Spots number
TiO ₂ NPs (5ppm)	32
TiO ₂ NPs (1ppm)	23
ZnO NPs (5ppm)	51
ZnO NPs (1ppm)	55
CuO NPs (5ppm)	103
CuO NPs (1ppm)	35
Ag (5ppm)	84
Ag (1ppm)	41

B




691

692


693 **Figure 3:** A) Representative 2D-DIGE with identified proteins and correspondent ID spot number. B) The
 694 protein expressions of the identified ID spots are illustrated as mean \pm SEM based on fold change ratio
 695 value for the differentially expressed proteins and classified according to biological functions.

696
 697



698
 699

700 **Figure 4:** Distribution of total lipid content in control and exposures to NPs. A) Pie charts from
 701 percentages of lipid species; B) Ratio phosphatidylcholine/phosphatidylethanolamine and cholesterol/
 702 phospholipid; C) Total lipid and total triacylglycerol in nmol/ mg protein TG, triacylglycerol; CL,
 703 cholesterol, CE, cholesteryl ester; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS,
 704 phosphatidylserine; PI, phosphatidylinositol; SM, sphingomyelin. Total lipid value corresponds to the
 705 summation of all measured lipid species, which are expressed as the percentage of the summation. Total
 706 phospholipid (PL) value corresponds to the summation of PC, PE, SM, PS and PI and total CL to the
 707 summation of FC and CE. Data are expressed as the mean \pm SEM and correspond to the results obtained
 708 using 5 mg/L concentration of NPs in the culture medium. Control vs. treated: * $P \leq 0.05$, *** $P \leq 0.001$.
 709



710
 711
 712

713 **TABLES**

714 **Table 1:** Characterization of Nanoparticles (NPs). NPs properties in powder form and dispersed in
 715 hepatocytes media. Ag-NPs: Zeta-potential values are not showed (-) due to several aggregations. SEM
 716 images of the largest NPs (i.e. CuO- and ZnO-NPs while TEM pictures for the other NPs were taken.
 717 Information about NPs properties from the powder (or liquid form for Ag-NPs) was provided from the
 718 manufacturing companies.

719

NPs	Purity (%)	Crystal structure	Powder		Suspension		
			Size (nm)	Specific surface area (M ² /g)	Concentration ppm	Size (nm)	Z-potential (mV)
TiO ₂	99+	Rutile	1-3	470	5	6.6e ⁴	-0.5±0.1
					500	1034e ⁵	-0.9±0.6
ZnO	79.8	Hexagonal	<100	15-25	5	440.7±110.7	-4.6±1.0
		Wurtzite			500	747.4±3.9	-8.2±0.4
CuO	77.3	Monoclinic	<50	29	5	-	4.0±5.6
		Crystals			500	939.6±10.6	-7.4±2.7
Ag	99+	Spheres	10	60	5	85.4±5.6	-8.5±2.5
					500		

720

721

722

723

724

725

726

727

728

729 **Table 2:** List of identified proteins by nano-LC-MS/MS after selection from the differentially expressed
 730 proteins ($p < 0.05$ and with fold change ≥ 1.5) and in common with at least two NPs exposures included the
 731 comparison control versus all NPs treatments.

Spot no	Accession no	ID protein	Theor. /Obs. pI	Theor. Mr (Da)	Obs. Mr (Da)	Mascot score	SC (%)	Peptide sequence (if only one peptide)	Functional pathway	Subcellular location
25	gi 124248512	Carbamoyl-phosphate synthase	6.48/~6	165711	~150000	2125	48		Urea cycle	Mitochondrion
28	gi 183396771	60 kDa heat shock protein	5.91/~4.8	61088	52000-76000	1677	57		Chaperone	Mitochondrion matrix
34	gi 1352250	Aldehyde dehydrogenase	7.53/~6.2	57015	38000-52000	309	13		Alcohol metabolism; Aldehydes oxidation	Mitochondrion matrix
49 102	gi 13637776	Alpha-enolase	6.37/~5.8	47453	38000-52000	943 267	67 32		Carbohydrate degradation, glycolysis	Cytoplasm; Cell membrane
91	gi 61252474	Hydroxy-methylglutaryl-CoA synthase	8.65/~7	57300	38000-52000	310	31		Lipid synthesis	Mitochondrion
209	gi 416677	ATP synthase subunit alpha	9.22/~5.8	59830	38000-52000	176	12		ATP synthesis, Transport	Mitochondrion
222	gi 81918016	Heterogeneous nuclear ribonucleoprotein F	5.31/~5.2	46043	~38000	116	9	K.ITGEAFVQ FAQFASQEL AEK.A	Nucleotide binding; single-stranded RNA binding	Nucleus
225	gi 341941780	Cytochrome b-c1 complex subunit 1	5.81/~4.8	53446	31000-38000	115	26		Mitochondrial electron transport	Mitochondrion inner membrane
227	gi 342187137	Mitochondrial 3-oxoacyl-CoA thiolase	8.33/~9	42260	31000-38000	1355	74		Lipid metabolism	Mitochondrion
230	gi 55977481	Tubulin beta-4B chain	4.79/~4.2	50255	38000-52000	2337	64		Structural molecule activity	Cytoplasm, cytoskeleton
249	gi 92090596	Electron transfer flavoprotein subunit beta	8.24/~8.2	27834	17000-24000	480	45		Electron carrier activity	Mitochondrion matrix
273	gi 46397464	ATP-dependent RNA helicase eIF4A-1	5.32/~5.8	46353	~31000	64	4	K.TATFAISIL QQIELDLK.A	Helicase	-
342	gi 146345417	Electron transfer flavoprotein subunit alpha	8.62/~7	35330	17000-24000	2282	66		Electron carrier activity	Mitochondrion matrix
497	gi 68775966	Tubulin beta-6 chain)	4.79/~4.2	50255	52000-76000	45	12	K.GHYTEGA ELVDSVLDV VR.K	Structural molecule activity	Cytoplasm, cytoskeleton
572	gi 54037181	Guanine nucleotide-binding protein subunit beta-2-like 1	7.60/~5.8	35511	12000-17000	68	24		Developmental protein	Cell membrane, cell projection cytoplasm, cytoskeleton, nucleus

732

733